KarX-EC: Clinical Trials

9 trials of KarX-EC, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

9 recruiting. 9 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 39Recruiting 9

Follow KarX-EC: new trials by email Literature Review of KarX-EC trials Research Report on KarX-EC

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder
Phase 3RecruitingBristol-Myers Squibb1762026-10-062026-11-10
A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Spectrum Disorder
KarXT, KarX-EC, KarXT + KarX-EC Matching Placebo - Irritability Associated With Autism Spectrum Disorder
Phase 3RecruitingBristol-Myers Squibb1762026-10-062026-11-10
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
KarXT, KarX-EC - Schizophrenia, Autism-Related Irritability
Phase 3RecruitingKaruna Therapeutics, Inc., a Bristol Myers Squibb company4002026-04-072026-11-06
A Study to Evaluate Safety and Efficacy of KarXT + KarX-EC as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-5)
KarXT, KarX-EC, KarXT + KarX-EC Arm Matching Placebo - Alzheimer Disease, Psychosis
Phase 3RecruitingBristol-Myers Squibb3252026-03-252026-06-30
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
KarXT, KarX-EC - Alzheimer Disease, Agitation
Phase 3RecruitingBristol-Myers Squibb6502025-12-022026-11-12
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
KarXT, KarX-EC, Placebo - Alzheimer's Disease
Phase 3RecruitingBristol-Myers Squibb5862025-07-212026-11-17
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer's Disease
Phase 3RecruitingBristol-Myers Squibb4262025-07-162026-11-03
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease
KarXT, KarX-EC, Placebo - Alzheimer's Disease
Phase 3RecruitingBristol-Myers Squibb5862025-07-142026-11-17
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Capsule, Placebo - Alzheimer Disease
Phase 3RecruitingBristol-Myers Squibb4262025-07-102026-11-06

Conditions studied

Alzheimer Disease (6)  ·  Dementia (3)  ·  Autism Spectrum Disorder (2)  ·  Cognitive Dysfunction (2)  ·  Psychomotor Agitation (2)  ·  Autistic Disorder (1)  ·  Psychotic Disorders (1)  ·  Schizophrenia (1)

Sponsors

Bristol-Myers Squibb (8)  ·  Karuna Therapeutics, Inc., a Bristol Myers Squibb company (1)

Countries

United States (9)  ·  Canada (6)  ·  France (6)  ·  Japan (6)  ·  Poland (6)  ·  Puerto Rico (6)  ·  Romania (6)  ·  Spain (6)  ·  Argentina (5)  ·  Australia (5)  ·  Germany (5)  ·  India (5)  ·  Brazil (4)  ·  Greece (4)  ·  Hungary (4)

NIH funding

2025 (6)